Summary: One of the major immune checkpoints responsible for immune evasion in cancer cells is the interaction between programmed cell death-1 (PD-1) and its ligand (PD-L1). As human trophoblastic cells display many of the features of malignant cells such as the ability to invade normal tissue including blood vessels and are apparently not eradicated by the host immune system, we undertook the present study to determine whether PD-L1 was upregulated in different types of trophoblastic cells during normal pregnancy and in gestational trophoblastic diseases. Immunohistochemistry using an anti-PD-L1-specific antibody demonstrated that in early and term normal placentas, PD-L1 was highly expressed in syncytiotrophoblast and to a much lower extent in intermediate trophoblastic cells located in the chorion laeve and implantation site. PD-L1 immunoreactivity was undetectable in cytotrophoblastic cells. This staining pattern in normal placenta was recapitulated in various types of gestational trophoblastic disease. PD-L1 was highly expressed by syncytiotrophoblast in complete moles and choriocarcinomas. The intermediate trophoblastic neoplasms, placental site trophoblastic tumors, and epithelioid trophoblastic tumors showed variable PD-L1 immunoreactivity but at a lower intensity than in the neoplastic syncytiotrophoblast in choriocarcinoma. In addition, we observed PD-1-positive lymphocytes located within the implantation site and in trophoblastic tumors. In summary, this study describes a novel mechanism for trophoblastic cells to create a tolerogenic feto-maternal interface by upregulating PD-L1 in syncytiotrophoblast and in intermediate trophoblast.
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Escape from immune surveillance and prevention of subsequent rejection by the host immune system are fundamental to sustain embryonic and fetal development in the uterus, as they express allogeneic paternal antigens. This immunologic paradox of pregnancy remains mainly unclear. As it is the trophoblast that directly interacts with the maternal environment, research has largely focused on elucidating how trophoblastic cells contribute to local immune suppression. For example, lack of MHC class II antigens on trophoblast is thought to facilitate survival of the semiallogeneic conceptus in the presence of maternal lymphocytes. CCL5 is a chemokine secreted by T cells that modulates the balance of maternal Treg/T-effector lymphocytes in promoting maternal tolerance of trophoblast (1) . It has been reported that human leukocyte antigen-G (HLA-G) is highly expressed by the extravillous (intermediate) trophoblastic cells in the trophoblastic columns, implantation site, and the chorion laeve but not in syncytiotrophoblast or cytotrophoblast (2) . The constitutive expression of HLA-G on these cells plays an important role in inducing immunotolerance by inhibiting cytotoxicity mediated by natural killer (NK) cells (3) (4) (5) (6) and T cells (7) (8) (9) . In addition, the finding of decreased protein and mRNA levels of indoleamine 2,3-dioxygenase in the placenta and decidua from recurrent spontaneous abortuses suggests an important role for indoleamine 2,3-dioxygenase in the maintenance of normal pregnancy (10) . It has also been suggested that during pregnancy the programmed cell death-1 (PD-1) pathway can modify the maternal decidual lymphocyte cytokine secretion facilitating immune suppression (11) .
In recent years, immune checkpoints have received significant attention in cancer research, among them, PD-1 is one of the best characterized checkpoint proteins. The interaction between PD-1 and its ligand, PD-L1, triggers signal transduction pathways that result in T-cell suppression, allowing PD-L1-expressing cancer cells to escape eradication by PD-1-positive immune cells. It has been reported that PD-L1 is expressed in various tumor types including non-small cell lung cancer, colorectal carcinoma, renal cell carcinoma, melanoma, and hematopoietic malignancies (12, 13) . Neutralization of PD-1 pathway activity by antibodies against PD-1 is considered a promising anticancer strategy alone or in combination with other immune-based therapy (13, 14) . In nongestational endometrium, the density of PD-1 + /CD3 + lymphocytes was lower than in the first trimester placental sites, suggesting that PD-L1-expressing trophoblast may exploit PD-1/PD-L1-mediated immune suppression in normal gestation. In fact, it has been reported that pregnant mice treated with anti-PD-L1 blocking antibody lose their embryos (15) and a deficiency in PD-L1 has been associated with an increased frequency of fetal resorption and decreased fetal survival (7). In view of these studies showing the functional roles of PD-L1 in mouse models, we undertook the present study to determine the expression pattern of PD-L1 in human placentas at various gestational ages and in various types of gestational trophoblastic disease (GTD).
MATERIALS AND METHODS

Tissues and Case Selection
The Pathology Diagnosis System was used to identify cases from the Surgical Pathology files and the gynecologic pathology division consultation files in the Department of Pathology, the Johns Hopkins Hospital, Baltimore, Maryland. Hematoxylin and eosin-stained sections were reviewed from each case to confirm the original diagnosis. Formalin-fixed paraffin-embedded tissue blocks were then retrieved from 16 first-trimester abortuses (including 6 showing an exaggerated placental site), 5 normal-term placentas, 7 complete hydatidiform moles, 11 placental site nodules, 35 choriocarcinomas, 6 placental site trophoblastic tumors (PSTTs), and 14 epithelioid trophoblastic tumors (ETTs). Sections of normal breast, small and large intestines, pancreas, salivary glands, gallbladder, brain, tonsils, kidney, lung, lymph node, tonsil, and stomach were used as normal controls. Most of the specimens were arranged in tissue microarrays to facilitate immunohistochemistry. All samples were anonymous and collection of the archived paraffin tissues was approved by the Johns Hopkins institutional review board.
Immunohistochemistry
Immunohistochemistry was performed at the Johns Hopkins Oncology Tissue Services using a rabbit monoclonal anti-PD-L1 antibody (Cell Signaling #13684 S) and a mouse monoclonal anti-PD-1 (Abcam, ab52587) antibody. After deparaffinization and hydration, slides were incubated in a Target Retrieval solution (Dako) and steamed for 45 min. The slides were then blocked with a Dual Blocking solution (Dako) for 5 min, followed by incubation with either of the primary antibodies as mentioned above at room temperature for 45 min, followed by poly-HRP anti-mouse or anti-rabbit secondary antibodies for 30 min. 3,3 0 -Diaminobenzidine (Sigma) was applied onto the slides to develop the immunoreactivity on tissues. For counter-staining, Dako Mayers hematoxylin (Dako, 1:5) was applied for 1 min. After washes, the slides were dehydrated, cleaned, and mounted with coverslips using xylene.
RESULTS
The immunostaining pattern of PD-L1 in normal placentas is summarized in Table 1 . PD-L1 immunoreactivity was intense on the outer surface of syncytiotrophoblast on chorionic villi in all early and term placentas (Fig. 1A) . Interestingly, the inner aspect of the syncytiotrophoblast, facing the chorionic villous stroma, was mostly negative. In contrast to syncytiotrophoblast, the cytotrophoblastic cells on the villi showed undetectable PD-L1 immunoreactivity (Fig. 1A) . The intermediate trophoblastic cells in implantation sites from both early and term placentas demonstrated either undetectable or very weak and focal staining (Figs. 1B, C) . The immunointensity of PD-L1 in exaggerated placental sites was similar to those in normal implantation sites. None of them had an immunointensity comparable to that in syncytiotrophoblast. Likewise, the intermediate trophoblastic cells in the chorion laeve (fetal membrane) showed either very weak or undetectable PD-L1 staining. The pattern of PD-L1 staining was predominantly membranous, with no nuclear or cytoplasmic localization. PD-L1 immunoreactivity was not detectable in normal breast, small and large intestines, pancreas, salivary glands, gallbladder, brain, tonsils, kidney, lung, lymph node, tonsil, and stomach, which were also included in tissue microarrays.
PD-L1 immunohistochemistry was performed on 68 gestational trophoblastic lesions. The staining pattern in complete hydatidiform moles was identical to the normal placentas. PD-L1 immunoreactivity was intense in syncytiotrophoblast and to a much lesser extent in implantation site intermediate trophoblastic cells, whereas cytotrophoblastic cells were virtually negative (Fig. 1D ). In choriocarcinoma, 22 (73%) of 30 specimens showed intense and diffuse PD-L1 immunoreactivity in syncytiotrophoblast and weaker immunoreactivity in intermediate trophoblastic cells. Three (10%) choriocarcinomas showed weak staining and 5 choriocarcinomas were negative for PD-L1 immunoreactivity (Table 2 and Fig. 2 ). In these cases there was a paucity of viable trophoblast; most of the tissue was necrotic. The expression levels of PD-L1 in intermediate trophoblastic tumors including PSTT and ETT varied from undetectable to intense staining (Fig. 3) . We did not observe PD-L1 immunoreactivity in any of the placental site nodules.
We also assessed the expression of PD-1 in immune cells in the same cohort of normal placentas and trophoblastic neoplasms. PD-1-positive immune cells were scattered in the implantation sites of early placentas and the density of positive cells varied from 1 to 7 per high-power field (40 Â ) (Figs. 4A, B) . In gestational trophoblastic tumors, PD-1-positive immune cells were present in association with PSTT, ETT, and choriocarcinomas but again their density varied widely from 0 to 5 positive cells per highpower field (Figs. 4C, D) . In general, the PD-1-positive immune cells were enriched in the areas with a high density of lymphocytes. PD-1 immunoreactivity was detected in lymphocytes of tonsils and lymph nodes but not in other normal tissues examined including breast, small and large intestines, pancreas, salivary glands, gallbladder, brain, kidney, lung, and stomach.
DISCUSSION
Survival of the developing embryo and fetus requires immune tolerance by inactivating the maternal immune system at the placental-maternal interface, which is thought to be accomplished by trophoblast. In the human placenta, there are different types of trophoblastic cells based on their locations, distinct gene expression profiles, and specific functions (16) . These include cytotrophoblast, which is the germinative component, syncytiotrophoblast, which is the terminally differentiated component and responsible for most of the functional activity of trophoblast, and intermediate trophoblast (extravillous trophoblast), which plays an important role in establishing the maternal-fetal blood circulation (16) (17) (18) . Among the various trophoblastic subpopulations, syncytiotrophoblast forms a continuous layer of tissue that extends and covers all surfaces of villous trees and part of the inner surface of chorionic and basal plates (17) where it is immersed in the maternal blood in the intervillous space. In contrast, intermediate trophoblastic cells are in close contact with immune cells either in the implantation site or in fetal membranes. In this study, we found that syncytiotrophoblast highly expresses PD-L1, whereas cytotrophoblast does not and intermediate trophoblast expresses little or no PD-L1, a result suggesting that syncytiotrophoblast uses PD-L1 as the immune checkpoint to inactivate PD-1-expressing immune cells. The molecular mechanisms accounting for PD-L1 upregulation in syncytiotrophoblast are unclear but they may involve a complex interaction of regulatory T cells, cytokines, chemokines, and growth factors derived from the feto-placental environment, which can directly or indirectly upregulate PD-L1 expression (19) . In neoplastic tissues, expression of PD-L1 was augmented in an EGFR-dependent and JAK2/STAT1-dependent manner in head and neck carcinoma (20) , and targeting the PD-1/PD-L1 signaling axis using a specific JAK2 inhibitor enabled blocking of PD-L1 upregulation in tumor cells and enhanced their immunogenicity. As EGFR is expressed by both normal and neoplastic syncytiotrophoblast (21) , it is possible that the EGF pathway may also participate in regulating PD-L1 expression. IFN-g is a proinflammatory cytokine secreted by uterine NK cells in the endometrium during early pregnancy (22) . Trophoblastic cells are known to increase IFN-g expression by a variety of microenvironment stimuli including CD56 + decidual NK cells (23) . IFN-g, in turn, upregulates PD-L1 because, like EGFR, IFN-g also utilizes Janus kinase 2 (JAK2) as a signaling mediator (24) .
The relatively low expression levels of PD-L1 in intermediate trophoblastic cells as compared with syncytiotrophoblast suggest that intermediate trophoblastic cells use other mechanisms to overcome surveillance by the maternal immune system. In fact, upregulation of HLA-G, a unique nonclassical MHC class I molecule, has been reported to be expressed exclusively in the intermediate trophoblastic cells but not in syncytiotrophoblast or cytotrophoblast (2, 25, 26) . Intermediate trophoblastic cells establish a tolerogenic microenvironment through the interaction with maternal innate and adaptive cells (27) . Specifically, HLA-G can present with nonamer peptides and bind CD8 in an analogous manner to classical HLA-class I proteins, facilitating the escape of immune surveillance (alloreactivity) by host T lymphocytes and NK cells (28, 29) . As PD-1-positive lymphocytes were detected in many GTD tissues as in a normal placental site (30) , it is likely that PD-L1-expressing syncytiotrophoblast works in conjunction with HLA-G-expressing intermediate trophoblastic cells to shield the entire gestational sac and fetus from attack by maternal immune cells.
GTD encompasses a heterogenous group of lesions with specific clinical features, morphologic characteristics, and pathogenesis (16) . The recent World Health Organization classification of GTD includes abnormally formed placentas (complete, partial hydatidiform mole, and invasive mole), trophoblastic neoplasms (choriocarcinoma, PSTT, and ETT), and non-neoplastic tumor-like lesions (exaggerated placental site and placental site nodule) (31) . In this study, we demonstrated high expression levels of PD- L1 in syncytiotrophoblast from complete moles and choriocarcinomas. Moreover, PD-L1 immunoreactivity, although generally weak, was detected in the tumor cells morphologically corresponding to intermediate trophoblastic cells in choriocarcinoma, PSTT, and ETT. Placental site nodules were negative for PD-L1. The above findings suggest that the expression pattern of PD-L1 is retained in GTD as in the normal placenta. Although this study reports the PD-L1/PD-1 immune checkpoint in syncytiotrophoblast, other checkpoint pathways should also be studied to determine whether they also operate in human trophoblastic cells to suppress local immunity. Besides PD-1, the checkpoint molecules known so far include cytotoxic T-cell antigen-4 (CTLA-4), T-cell immunoglobulin mucin-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and B-cell and T-cell lymphocyte attenuator (BTLA), which serve as negative regulators of activated cytotoxic T cells (32) . Future studies to demonstrate whether there is a positive association between loss of these immune checkpoint molecules and infertility or spontaneous abortion would provide further support that they are important in immune tolerance during pregnancy.
In conclusion, this study provides new data showing that different trophoblastic populations may utilize different immune suppressive mechanisms to ensure tolerance of conceptus. Normal and neoplastic syncytiotrophoblast highly expresses PD-L1, a ligand for PD-1 immune checkpoint receptor, whereas intermediate trophoblastic cells express much lower PD-L1 and cytotrophoblastic cells do not have detectable PD-L1 immunoreactivity. Thus, the PD-1 and PD-L1 pathway may represent one of the main mechanisms for syncytiotrophoblast that collaborates with HLA-G- 152 E. VERAS ET AL.
